Phase II Study to Assess Safety & Immunogenicity of Multimeric-001 Influenza Vaccine, Followed by TIV
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
This is a single-site, randomized, double-blind, placebo-controlled study of Multimeric-001
in thirty six (36) volunteers 50-65 years of age.
All subjects will receive an intramuscular (IM) injection, in each one of three visits, with
a 21±2 days interval between treatments.